Syneron obtains FDA approval for UltraShape

Non-invasive UltraShape uses pulsed focused ultrasound energy to remove fat.

Syneron Medical Ltd. (Nasdaq: ELOS) has obtained US Food and Drug Administration (FDA) approval for its non-invasive UltraShape System for fat cell destruction. The product obtained CE Mark in 2005, and is sold in Europe, Canada, and in Asia Pacific countries.

The UltraShape System is the first and only non-invasive body shaping treatment that uses pulsed focused ultrasound energy that targets subcutaneous fat, while keeping the surrounding tissue, vasculature, nerves and muscles intact.

Syneron acquired UltraShape Ltd., which developed the device, in 2012, and subsequently sought to obtain FDA approval for the product. The company sais that the device has been used in over 220,000 procedures worldwide

"The UltraShape technology is one of the two pillars of our body shaping strategy," said Syneron chairman Dr. Shimon Eckhouse. "Our significant investment in the development of non-invasive body shaping products puts us in a unique position to lead the market with UltraShape mechanical fat destruction technology, and with our unique VelaShape III elōs based thermal technology. With these two FDA cleared technologies we have a wide range of body shaping indications including circumferential reduction in various body areas and reduction in cellulite appearance. These two complementary technologies will be key factors for serving our global customer base in the fast growing body shaping market."

Published by Globes [online], Israel business news - - on April 16, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018